Cyn3rgy Research is conducting a 12-Week, Phase 4, Open-Label Study to Assess Safety, Pharmacokinetics, and Treatment Effect of CABTREO™ (Clindamycin Phosphate 1.2%, Adapalene 0.15%, and Benzoyl Peroxide 3.1%) Topical Gel in Pediatric Participants Ages 9 To 11 Years, 11 Months with Acne Vulgaris.

Qualified participants will be compensated for time and travel.